Filing search / Innovation Pharmaceuticals Inc. / "Litigation"

8-K

EX-10.1

qrgls32io1i mpyo2

15 Jun 22

Entry into a Material Definitive Agreement

4:00pm

8-K

EX-99.1

env g9ygtc1clf

15 Jun 22

Entry into a Material Definitive Agreement

4:00pm

8-K

EX-99.1

p9t20fuv

15 Jan 21

Innovation Pharmaceuticals’ Brilacidin for the Treatment of COVID-19 Receives

12:35pm

8-K

EX-99.1

l7ph2d4jf54

22 Dec 20

FDA Grants IND Approval for Phase 2 Clinical Trial of Innovation Pharmaceuticals’ Brilacidin for Treating COVID-19

9:00am

8-K

EX-3.1

reb65ej2i8ncwwyc1lu

10 Dec 20

Entry into a Material Definitive Agreement

12:00am

8-K

EX-10.1

0ydah8rppk5t 6981r77

10 Dec 20

Entry into a Material Definitive Agreement

12:00am

424B5

o9o lwgz9l

10 Dec 20

Prospectus supplement for primary offering

12:00am

8-K

EX-99.1

ztpuzjt8

16 Nov 20

Innovation Pharmaceuticals Announces Overseas Regulatory Filing Submitted For COVID-19 Clinical Study

12:47pm